RGENIX, INC.
Biotech · Private
RGX-104, an orally available small-molecule Liver X receptor (LXR) agonist therapeutic for metastatic melanoma
rgenix.com →- Grants
- $2.2M
- 2 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 31
- 7 granted · 24 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620172018
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Development of an LXR agonist as first in class therapy for treatment of metastatic melanoma | $1,639,260 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of an LXR agonist as first in class therapy for treatment of metastatic melanoma | $521,277 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2072 | Slingshot Biosciences | — | $24M |
| 2073 | ANI Energy, LLC | — | $1.5M |
| 2074 | Key Health Institute of Edmond, LLC | — | $100K |
| 2075 | RGENIX, INC. | — | — |
| 2076 | Outpost Intros Inc. | — | $475K |
| 2077 | Leal Therapeutics | — | — |
| 2078 | PHOENIX PHARMALABS, INC. | — | $3.5M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- High-affinity Anti-mertk Antibodies And Uses Thereofgranted
- Inhibitors Of Creatine Transport And Uses Thereofgranted
- Lxr Agonists And Uses Thereofgranted
- Pharmaceutically Acceptable Salts Of Beta-guanidinopropionic Acid With Improved Properties And Uses Thereofapplication
- Pharmaceutically Acceptable Salts Of B-guanidinopropionic Acid With Improved Properties And Uses Thereofgranted
- Inhibitors Of Creatine Transport And Uses Thereofgranted
- Treatment And Diagnosis Of Cancerapplication
- Pharmaceutically Acceptable Salts Of B-guanidinopropionic Acid With Improved Properties And Uses Thereofgranted
- Pharmaceutically Acceptable Salts Of B-guanidinopropionic Acid With Improved Properties And Uses Thereofgranted
- PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOFapplication
- Methods For The Treatment Of Cancerapplication
- Formulations with Improved Stabilityapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.